Corinne Iacobucci

Papers

1

Total Citations

12

H-Index

1

About

Dr. Corinne Iacobucci is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-mediated oropharyngeal cancer (OPC) and novel immunotherapy strategies. Her major contributions center on the development of response-adapted, de-escalation treatment paradigms designed to reduce long-term toxicity without compromising cure rates. Dr. Iacobucci is the principal investigator of the landmark TARGET-HPV trial, which investigates the neoadjuvant use of HB-200, an arenavirus-based immunotherapy targeting HPV16, followed by chemotherapy and response-stratified de-intensification of radiotherapy in HPV16+ OPC patients. This work, published in 2024, has already garnered significant attention with 12 citations, reflecting its high impact in a rapidly evolving field. By pioneering the integration of viral-specific immunotherapy into curative treatment pathways, Dr. Iacobucci is at the forefront of efforts to personalize therapy for HPV-driven cancers, offering the potential to spare patients from the debilitating side effects of traditional chemoradiation. Her research is instrumental in defining a new standard for biomarker-driven, de-escalation strategies in head and neck oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV.
12 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 18

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago